87S Stock Chart & Stats
€24.50
<€0.01(0.05%)
At close: 4:00 PM EST
€24.50
<€0.01(0.05%)
Day’s Range― - ―
52-Week Range€9.11 - €32.21
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€22.02B
Enterprise Value€19.08K
Total Cash (Recent Filing)€4.30B
Total Debt (Recent Filing)€107.44M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Aug 17, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding719,270,400
10 Day Avg. Volume0
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.25
Price to Sales (P/S)2326.88
P/FCF Ratio-25.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.57Price Target Upside28.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.05
Revenue Forecast (FY)€69.08M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Moderna SettlementA very large cash balance plus a material settlement payment materially extends Roivant's runway, funding late‑stage trials, commercialization build‑out and business development without near‑term financing. This durable optionality reduces dilution risk and supports multi‑year development plans.
Low Leverage, Well‑capitalized Balance SheetVery low debt and sizable equity provide financial flexibility typical biotech companies need for long development cycles. This structural strength enables continued R&D investment, potential M&A or partnerships, and resilience against trial delays without immediate refinancing pressure.
Pipeline Momentum And Clinical ExecutionRobust open‑label efficacy in a heavily refractory RA cohort and rapid enrollment across programs signal meaningful scientific differentiation and operational capability. Sustained execution reduces development timeline risk and supports commercial planning across multiple indications over the next 2–6 months.
Bears Say
Sustained Negative Cash GenerationPersistent large negative operating and free cash flows mean Roivant will continue to consume liquidity while advancing programs. Even with ample cash today, continued burn raises dependency on milestone receipts, settlements or financing, increasing execution and dilution risk over the medium term.
Ongoing Operating Losses And Shrinking RevenueLarge recurring operating losses and a material decline in trailing revenue indicate the company is not yet generating sustainable commercial earnings. Over several quarters this undermines return potential on capital and heightens reliance on successful launches or asset monetizations to reach profitability.
Clinical Design And Interpretability Risk For 1402The chosen randomized‑withdrawal primary endpoint and reliance on open‑label Period‑1 data introduce durable regulatory and evidentiary risk: deep responses can reduce separation in a short withdrawal window, and placebo‑controlled interpretability is limited. Potential for additional studies or regulatory delay exists.
Roivant Sciences News
87S FAQ
What was Roivant Sciences Ltd.’s price range in the past 12 months?
Roivant Sciences Ltd. lowest stock price was €9.11 and its highest was €32.21 in the past 12 months.
What is Roivant Sciences Ltd.’s market cap?
Roivant Sciences Ltd.’s market cap is €22.02B.
When is Roivant Sciences Ltd.’s upcoming earnings report date?
Roivant Sciences Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 25 days.
How were Roivant Sciences Ltd.’s earnings last quarter?
Roivant Sciences Ltd. released its earnings results on May 20, 2026. The company reported €0.244 earnings per share for the quarter, beating the consensus estimate of -€0.253 by €0.497.
Is Roivant Sciences Ltd. overvalued?
According to Wall Street analysts Roivant Sciences Ltd.’s price is currently Undervalued.
Does Roivant Sciences Ltd. pay dividends?
Roivant Sciences Ltd. does not currently pay dividends.
What is Roivant Sciences Ltd.’s EPS estimate?
Roivant Sciences Ltd.’s EPS estimate is -0.25.
How many shares outstanding does Roivant Sciences Ltd. have?
Roivant Sciences Ltd. has 719,270,400 shares outstanding.
What happened to Roivant Sciences Ltd.’s price movement after its last earnings report?
Roivant Sciences Ltd. reported an EPS of €0.244 in its last earnings report, beating expectations of -€0.253. Following the earnings report the stock price went up 1.349%.
Which hedge fund is a major shareholder of Roivant Sciences Ltd.?
Currently, no hedge funds are holding shares in DE:87S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roivant Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€31.57 (28.84% Upside)
€31.57 (28.84% Upside)
Blogger Sentiment
Bullish
DE:87S Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €183.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
204.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.35%
Trailing 12-Months
Company Description
Roivant Sciences Ltd.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
87S Stock 12 Month Forecast
Average Price Target
€31.57
▲(28.84% Upside)